Taipei, July 22 (CNA) A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Mandarin Airlines begins services between Songshan and Matsu's Nangan
03/26/2023 10:45 PM - Society
CECC sees no rise in COVID-19 cases after case reporting ends
03/26/2023 10:26 PM - Cross-Strait
Ma Ying-jeou Foundation blames Tsai's policy failures for Honduras loss
03/26/2023 10:19 PM - Politics
Hondurans in Taiwan reckon with future after diplomatic split
03/26/2023 10:01 PM - Cross-Strait
Different motives seen behind Beijing's poaching of Honduras
03/26/2023 09:24 PM